5.10
+0.12(+2.41%)
Currency In USD
Address
500 Technology Square
Cambridge, MA 02139
United States of America
Phone
617 586 3100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
112
First IPO Date
October 23, 2020
| Name | Title | Pay | Year Born |
| Mr. Adrian H. B. Gottschalk | President, Chief Executive Officer & Director | 885,701 | 1976 |
| Ms. Karin Hellsvik | Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs & Investor Relations | 0 | N/A |
| Dr. Alfonso Quintas Cardama M.D. | Chief Medical Officer | 300,161 | 1971 |
| Dr. Anna Rivkin Ph.D. | Chief Business Officer | 348,672 | 1974 |
| Mr. Michael J. LaCascia J.D. | Chief Legal Officer | 565,500 | 1965 |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer | 572,600 | 1965 |
| Mr. Kristian Humer M.B.A. | Chief Financial Officer | 637,806 | 1976 |
| Dr. Gerald R. Crabtree M.d. | Founder & Member of Scientific Advisory Board | 0 | N/A |
| Mr. Carlos Costa | Chief People Officer | 0 | 1973 |
| Mr. Saurabh Sewak Ph.D. | Vice President of Corporate Development | 0 | N/A |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.